Compare Bristol-Myers Squibb Co (BMY) vs Global X Defense Tech ETF (SHLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Global X Defense Tech ETF — how do they compare? Bristol-Myers Squibb Co trades at $57 (market cap $116.30B), while Global X Defense Tech ETF trades at $60.22. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while Global X Defense Tech ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, Global X Defense Tech ETF nearer its low. Which is the better fit depends on your goals.
| BMY | SHLD | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Sector/Thematic |
52-Week High | $62.37 | $78.02 |
52-Week Low | $42.60 | $58.20 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
SHLD (Global X Defense Tech ETF) trades at $60.47, down 1.18% today amid bearish technical signals. The ETF faces selling pressure with moving averages indicating a downtrend, though oscillators remain neutral. Recent news highlights defense sector opportunities from global military spending increases and geopolitical tensions, with SHLD positioned as a diversified play on defense technology innovation across international markets.
Outlook remains mixed with technical weakness offset by positive sector catalysts. Investment opportunity lies in exposure to rising global defense budgets and technological modernization, but risks include political uncertainty and competition from specialized ETFs. The bearish technical setup suggests cautious entry points near support levels may be prudent for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Global X Defense Tech ETF
SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →
